Are you interested in the clinical use of #CARTcells and learning more about the future potential of research? @SWECARNET, will hold an Educational Day on April 27th, 2022, where our CSO, Professor Magnus Essand, will present. news.cision.com/elicera-therap…

Exciting new work from @MagnusEssand’s group published in Nat Biomed Eng. reporting how arming CAR-T cells with neutrophil-activating protein (NAP) can improve their efficacy in solid tumors Congratulations @ChuanJin JingMa Mohan @DiYu 👏 nature.com/articles/s4155…

Curious on how we modified blood vessels to boost immunity and treat brain cancer? 💉🧠 Our new publication is out now on Cancer Cell ! Big congrats to the first authors of this work, Mohan , Alessandra Vaccaro & Tiarne van de Walle , and to the whole team 🥳 cell.com/cancer-cell/fu…

Online Now: Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma dlvr.it/Sp6vzN

Read this week's #ResearchWatch: AAV-Mediated Gene Delivery of LIGHT Prolongs Survival in #Glioblastoma, summarizing the work of Mohan, Alessandra Vaccaro, Tiarne van de Walle, Magnus Essand, DimbergLab et al. bit.ly/3q5eQLg @UU_University

Tonic signaling should always be considered when designing new CARs. View our paper in Nature Communications to find out how CDR regions of the CAR can effect tonic signaling and how to screen for it. Big congrats to first author Tina Sarèn and all co-authors.🎉 nature.com/articles/s4146…

I don't know if that's the only root cause of tonic signaling but great work by $ELIC researchers. Makes sense wrt $ACLX eg who don't use scFv's but D-Domains. Complementarity-determining region clustering may cause CAR-T cell dysfunction nature.com/articles/s4146…

Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program | Elicera Therapeutics, #cartcell, #tcell, #glioma, #CancerResearch, #cancer #celltherapy, #Immunotherapy, IGP_UU, @UU_University. nature.com/articles/s4146…

Curious to know the clinical outcome of our study and how characteristics of the CAR-T infusion products may effect? Read our latest publication in Clinical Cancer Research ! Thank you to everyone involved in this work😍Essand Lab Mohan #immunotherapy #CARTcell aacrjournals.org/clincancerres/…

Read our recent publication in Clinical Cancer Research on how characteristics of #CARTcell infusion product influences treatment outcome in #lymphoma patients. Congratulations to authors Tina Sarèn , Essand Lab from @UU_University at IGP_UU